Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

被引：0
|
作者：
Mei Dong
Zhi-Qiang Ning
Pu-Yuan Xing
Jia-Lian Xu
Hai-Xiang Cao
Gui-Fang Dou
Zhi-Yun Meng
Yuan-Kai Shi
Xian-Ping Lu
Feng-Yi Feng
机构：
[1] Chinese Academy of Medical Sciences,Department of Medical Oncology, Cancer Institute and Hospital
[2] Chipscreen Biosciences Ltd.,Laboratory of Drug Metabolism and Pharmacokinetics
[3] Tigermed Consulting Ltd.,undefined
[4] Institute of Transfusion Medicine,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Chidamide; HDAC inhibitor; Phase I; Solid tumor; Lymphoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1413 / 1422
页数：9
相关论文
共 50 条
  • [1] Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas
    Dong, Mei
    Ning, Zhi-Qiang
    Xing, Pu-Yuan
    Xu, Jia-Lian
    Cao, Hai-Xiang
    Dou, Gui-Fang
    Meng, Zhi-Yun
    Shi, Yuan-Kai
    Lu, Xian-Ping
    Feng, Feng-Yi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1413 - 1422
  • [2] Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity
    Zhi-Qiang Ning
    Zhi-Bin Li
    Michael J. Newman
    Song Shan
    Xin-Hao Wang
    De-Si Pan
    Jin Zhang
    Mei Dong
    Xin Du
    Xian-Ping Lu
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 901 - 909
  • [3] Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity
    Ning, Zhi-Qiang
    Li, Zhi-Bin
    Newman, Michael J.
    Shan, Song
    Wang, Xin-Hao
    Pan, De-Si
    Zhang, Jin
    Dong, Mei
    Du, Xin
    Lu, Xian-Ping
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 901 - 909
  • [4] CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells
    Gong, Ke
    Xie, Jia
    Yi, Hong
    Li, Wenhua
    BIOCHEMICAL JOURNAL, 2012, 443 : 735 - 746
  • [5] Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy
    Gao, Shuai
    Li, Xiaoyang
    Zang, Jie
    Xu, Wenfang
    Zhang, Yingjie
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2017, 17 (06) : 802 - 812
  • [6] HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors
    Shojaei, Farbod
    Goodenow, Bob
    Lee, Gloria
    Kabbinavar, Fairooz
    Gillings, Mireille
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [7] Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin's lymphoma: phase I safety and efficacy
    Yoshimitsu, Makoto
    Ando, Kiyoshi
    Ishida, Takashi
    Yoshida, Shinichiro
    Choi, Ilseung
    Hidaka, Michihiro
    Takamatsu, Yasushi
    Gillings, Mireille
    Lee, Gloria T.
    Onogi, Hiroshi
    Tobinai, Kensei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (09) : 1014 - 1020
  • [8] Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma: Phase IIb results
    Utsunomiya, Atae
    Izutsu, Koji
    Jo, Tatsuro
    Yoshida, Shinichiro
    Tsukasaki, Kunihiro
    Ando, Kiyoshi
    Choi, Ilseung
    Imaizumi, Yoshitaka
    Kato, Koji
    Kurosawa, Mitsutoshi
    Kusumoto, Shigeru
    Miyagi, Takashi
    Ohtsuka, Eiichi
    Sasaki, Osamu
    Shibayama, Hirohiko
    Shimoda, Kazuya
    Takamatsu, Yasushi
    Takano, Kuniko
    Yonekura, Kentaro
    Makita, Shinichi
    Taguchi, Jun
    Gillings, Mireille
    Onogi, Hiroshi
    Tobinai, Kensei
    CANCER SCIENCE, 2022, 113 (08) : 2778 - 2787
  • [9] A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors
    Nuttapong Ngamphaiboon
    Grace K. Dy
    Wen Wee Ma
    Yujie Zhao
    Thanyanan Reungwetwattana
    Dawn DePaolo
    Yi Ding
    William Brady
    Gerald Fetterly
    Alex A. Adjei
    Investigational New Drugs, 2015, 33 : 225 - 232
  • [10] A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors
    Ngamphaiboon, Nuttapong
    Dy, Grace K.
    Ma, Wen Wee
    Zhao, Yujie
    Reungwetwattana, Thanyanan
    DePaolo, Dawn
    Ding, Yi
    Brady, William
    Fetterly, Gerald
    Adjei, Alex A.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (01) : 225 - 232
12345